Journal of Blood Disorders & Transfusion

Lymphoma updates-What is new in 2016?

4^th International Conference on Blood Malignancies & Treatment

April 18-19, 2016 Dubai, UAE

Victor Yazbeck

Virginia Commonwealth University, USA

Posters & Accepted Abstracts: J Blood Disord Transfus

Abstract:

Malignant lymphomas are a heterogeneous group of diseases that can be divided into 2 major subtypes�??Hodgkin�??s lymphoma (HL) and non-Hodgkin�??s lymphomas (NHL). The incidence of NHL has been rising over the past 3 decades. Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma and the most common form of adult NHL. It can be further subdivided into the favorable germinal center B-cell-like (GCB) subtype or the unfavorable activated B-cell-like (ABC) subtype. Unlike aggressive lymphomas, indolent NHL (iNHL) remains largely incurable with current therapies. Several lymphoma subtypes such as Mantle cell lymphoma (MCL), T-cell lymphoma, ABC-DLBCL, and double-hit DLBCL are associated with poor outcome. Our understanding of the intracellular machinery and the signaling pathways involved in lymphoma cell growth and proliferation has allowed the identification of key targets for new agent combination. Currently, several novel therapies are being investigated either as single agents or in combinations with novel agents or standard chemotherapy. In addition, current clinical trials are designed to tailor therapy to the patient�??s tumor molecular characteristics. We will review the current therapies of NHL and HL, and discuss challenging cases about how lymphoma patients should be treated in 2016.

Biography :

Email: victor.yazbeck@vcuhealth.org